A RELIABLE MULTIGRAM SYNTHESIS OF (±) DOXAZOSIN

References

• 2000 . Drugs Future , 25 : 1311
   Google Scholar
• Guthrie , R. M. and Siegel , R. L. 1999 . Clin. Ther. , 21 : 1732
   PubMed Web of Science ®Google Scholar
• Elliot , H. L. , Meredith , P. A. and Reid , J. L. 1987 . Am. J. Cardiol. , 59 : 79G
   Google Scholar
• Kirby , R. S. 1998 . Int. J. Clin. Pract. , 52 : 402
   PubMed Web of Science ®Google Scholar
• Althuis , T. H. and Hess , H. J. 1977 . J. Med. Chem. , 20 : 146
   PubMed Web of Science ®Google Scholar
• Manoury , P. M. , Binet , J. L. , Dumas , A. P. , Lefevre-Borg , F. and Cavero , I. 1986 . J. Med. Chem. , 29 : 1925
   Google Scholar
• Buhler , F. R. , Amann , F. W. , Bolli , P. , Hulthen , L. , Kiowski , W. , Landmann , R. and Burgisser , E. 1982 . J. Cardiovasc. Pharmacol. , 4 : S134
   PubMed Web of Science ®Google Scholar
• Goldstein , D. S. 1983 . Hypertension , 5 : 86
   PubMed Web of Science ®Google Scholar
• Campbell , S. F. , Davey , M. J. , Hardstone , J. D. , Lewis , B. N. and Palmer , M. J. 1987 . J. Med. Chem. , 30 : 49 – 57 .
   PubMed Web of Science ®Google Scholar
• Kevin Fang , Q. , Grover , P. , Han , Z. , McConville , F. X. , Rossi , R. F. , Olsson , D. J. , Kessler , D. W. , Wald , S. A. and Senanayake , C. H. 2001 . Tetrahedron: Asymm. , 12 : 2169
   Google Scholar
• Campbell , S. F. UK Patent 2,007,656B . CA, 91: 74649u (1979)
   Google Scholar
• Campbell , S. F. US Patent 4,188,390 . CA, 91: 74649u (1999)
   Google Scholar
• Hess , H-J. US Patent 3,511, 836 . CA, 71: 91519f (1969)
   Google Scholar
• Koo , J. , Avakian , S. and Martin , G. J. 1955 . J. Am. Chem. Soc. , 77 : 5373
   Web of Science ®Google Scholar
• Arrault , A. , Guillaumet , G. , Leger , J-M. , Christian , J. and Merour , J-Y. 2002 . Synthesis , 13 : 1879
   Google Scholar
• The purity of the product (±) (3) was determined by GC and found to be 98% (5% OV-17, 100-250°C, 10°C/min)
   Google Scholar
• The US and Indian patent applications are under review (CSIR Ref. No. NF/538/01)
   Google Scholar
• Chou , W-C. , Tan , C-W. , Chen , S. F. and Ku , H. 1998 . J. Org. Chem , 63 : 10015
   Web of Science ®Google Scholar
• US Patents 6, 130,218 . Polymorphic form of doxazosin mesylate (Form I), CA, 129: 45312b (1998) and 6,140,334; CA, 129: 45310z (1998)
   Google Scholar
• The purity of the product (±) 4 was monitored by NMR and TLC. The NMR spectrum shows no trace of the bis-amde. We were unable to obtain a HPLC analysis of the product (±) 4 using YMC ODS 25cms, 5μ column (50:50 mixture of acetonitrile and methanol modified with 0.05% v/v TEA in water)
   Google Scholar
• The US and Indian patent applications are under review (CSIR Ref. No. NF/428/02). European Patent No. 02021686.7
   Google Scholar
• Process optimization for the direct resolution of (±) 4 is in progress
   Google Scholar
• The current ICH guideline for residual solvents in pharmaceutical active substances (ICH Guideline: Residual Solvents, Pharmeuropa, Vol. 8, No. 1, page 103, March 1996)
   Google Scholar
• A 100-kg batch production of this drug is currently under progress with Cadila Pharmaceuticals Ltd. Ahmedabad-380 009, Gujarat, India
   Google Scholar